Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $207 to $225.
February 08, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Ascendis Pharma and raises the price target from $207 to $225.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and a potential short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100